Skip to main content
Erschienen in:

17.08.2023 | short review

ASCO 2023: new treatment options in CNS tumors

Invited short review

verfasst von: Dr. Josef Pichler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Summary

Practice-changing therapy for IDH1/2–mutant diffuse glioma was presented at the meeting. Vorasidenib as an oral, brain penetrant, dual inhibitor of mutant IDH1/2 showed very promising results in the phase 3 INDIGO study. Other new treatment approaches including vaccines, immunotherapy and targeted therapy in rare von Hippel–Lindau-associated cerebral hemangioblastomas have shown progress in neuro-oncology.
Literatur
2.
Zurück zum Zitat Hartmann C, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–74.CrossRefPubMed Hartmann C, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–74.CrossRefPubMed
3.
5.
Zurück zum Zitat Wakimoto H, et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014;20(11):2898–909.CrossRefPubMedPubMedCentral Wakimoto H, et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014;20(11):2898–909.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat ClinicalTrials.gov Identifier: NCT03922555; ASTX727 in Recurrent/Progressive Non enhancing IDH Mutant Gliomas ClinicalTrials.gov Identifier: NCT03922555; ASTX727 in Recurrent/Progressive Non enhancing IDH Mutant Gliomas
8.
Zurück zum Zitat ClinicalTrials.gov Identifier: NCT05406700 Niraparib In Recurrent IDH 1/2 Gliomas ClinicalTrials.gov Identifier: NCT05406700 Niraparib In Recurrent IDH 1/2 Gliomas
Metadaten
Titel
ASCO 2023: new treatment options in CNS tumors
Invited short review
verfasst von
Dr. Josef Pichler
Publikationsdatum
17.08.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00915-z

Weitere Artikel der Ausgabe 4/2023

memo - Magazine of European Medical Oncology 4/2023 Zur Ausgabe